News

The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have

The $0.6m (4m yuan) deal, which will facilitate Lakeside’s entry into the medical logistics sector, is set to contribute an estimated $7m in annual revenues to the integrated

ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase

Situated in Milton Park, near Oxford, the new 30,000ft2 facility is part of NEB’s wholly-owned subsidiary network. The site is designed to offer solutions for ambient molecular biology

This partnership leverages SpectronRx’s advanced facilities for late-stage clinical and commercial supplies of the therapy. SpectronRx and Plus Therapeutics collaboration is set to accelerate nuclear medicine and improve

This epinephrine sublingual spray is designed for emergency situations. The FDA’s feedback could potentially lead the company to a New Drug Application (NDA) submission. The FDA-approved epinephrine prodrug

The partnership aims to accelerate the development of new treatments for eye diseases (ophthalmology) and cancer (oncology) as well as enhance the technologies for their production. This deal

This collaboration is set to streamline and scale up manufacturing of cell therapies for clinical trials in the future, with financial backing from the European Innovation Council (EIC) Accelerator

The FDA’s ODD status is granted to investigational assets for treating diseases affecting less than 200,000 people in the US. This designation provides incentives such as tax credits for